Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

Giovanni Paganelli, Stefania Zoboli, Marta Cremonesi, Lisa Bodei, Mahila Ferrari, Chiara Grana, Mirco Bartolomei, Franco Orsi, Concetta De Cicco, Helmut R. Mäcke, Marco Chinol, Filippo De Braud

Research output: Contribution to journalArticle

Abstract

A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23% of patients; 64% had stable and 13% progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.

Original languageEnglish
Pages (from-to)426-434
Number of pages9
JournalEuropean Journal Of Nuclear Medicine
Volume28
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Octreotide
Radiotherapy
Somatostatin Receptors
Maximum Tolerated Dose
Kidney
Yttrium
Neoplasms
Lymphopenia
Somatostatin
Radionuclide Imaging
Therapeutics
Radiation
Safety
Injections
DOTA-Tyr(3)-90Y-octreotide

Keywords

  • Y/In-DOTATOC
  • Peptides
  • Receptor-mediated radiotherapy
  • Somatostatin analogue

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. / Paganelli, Giovanni; Zoboli, Stefania; Cremonesi, Marta; Bodei, Lisa; Ferrari, Mahila; Grana, Chiara; Bartolomei, Mirco; Orsi, Franco; De Cicco, Concetta; Mäcke, Helmut R.; Chinol, Marco; De Braud, Filippo.

In: European Journal Of Nuclear Medicine, Vol. 28, No. 4, 2001, p. 426-434.

Research output: Contribution to journalArticle

@article{c03a0b242124439fbd8ea3ff2a72937b,
title = "Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide",
abstract = "A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23{\%} of patients; 64{\%} had stable and 13{\%} progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.",
keywords = "Y/In-DOTATOC, Peptides, Receptor-mediated radiotherapy, Somatostatin analogue",
author = "Giovanni Paganelli and Stefania Zoboli and Marta Cremonesi and Lisa Bodei and Mahila Ferrari and Chiara Grana and Mirco Bartolomei and Franco Orsi and {De Cicco}, Concetta and M{\"a}cke, {Helmut R.} and Marco Chinol and {De Braud}, Filippo",
year = "2001",
doi = "10.1007/s002590100490",
language = "English",
volume = "28",
pages = "426--434",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "4",

}

TY - JOUR

T1 - Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

AU - Paganelli, Giovanni

AU - Zoboli, Stefania

AU - Cremonesi, Marta

AU - Bodei, Lisa

AU - Ferrari, Mahila

AU - Grana, Chiara

AU - Bartolomei, Mirco

AU - Orsi, Franco

AU - De Cicco, Concetta

AU - Mäcke, Helmut R.

AU - Chinol, Marco

AU - De Braud, Filippo

PY - 2001

Y1 - 2001

N2 - A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23% of patients; 64% had stable and 13% progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.

AB - A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthesised for therapeutic purposes, because of its stable and easy labelling with yttrium-90. The aim of this study was to determine the dosage, safety profile and therapeutic efficacy of 90Y-DOTATOC in patients with cancers expressing somatostatin receptors. We recruited 30 patients with histologically confirmed cancer. The main inclusion criterion was the presence of somatostatin receptors as documented by 111In-DOTATOC scintigraphy. 90Y-DOTATOC was injected intravenously using a horizontal protocol: patients received equivalent-activity doses in each of three cycles over 6 months. The first six patients received 1.11 GBq per cycle and the four successive groups of six patients received doses increasing in 0.37-GBq steps. Toxicity was evaluated according to WHO criteria. No patient had acute or delayed adverse reactions up to 2.59 GBq 90Y-DOTATOC per cycle (total 7.77 GBq). After a total dose of 3.33 GBq, one patient developed grade II renal toxicity 6 months later. The maximum tolerated dose per cycle has not yet been reached, although transient lymphocytopenia has been observed. Total injectable activity is limited by the fact that the maximum dose tolerated by the kidneys has been estimated at 20-25 Gy. Complete or partial tumour mass reduction occurred in 23% of patients; 64% had stable and 13% progressive disease. It is concluded that high activities of 90Y-DOTATOC can be administered with a low risk of myelotoxicity, although the cumulative radiation dose to the kidneys is a limiting factor and requires careful evaluation. Objective therapeutic responses have been observed.

KW - Y/In-DOTATOC

KW - Peptides

KW - Receptor-mediated radiotherapy

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=0035094321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035094321&partnerID=8YFLogxK

U2 - 10.1007/s002590100490

DO - 10.1007/s002590100490

M3 - Article

C2 - 11357492

AN - SCOPUS:0035094321

VL - 28

SP - 426

EP - 434

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 4

ER -